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To understand the mechanism of Axl signaling, we have initiated studies to delineate downstream compo-
nents in interleukin-3-dependent 32D cells by using a chimeric receptor containing the recombinant epidermal
growth factor (EGF) receptor extracellular and transmembrane domains and the Axl kinase domain (EAK [for
EGF receptor-Axl kinase]). We have previously shown that upon exogenous EGF stimulation, 32D-EAK cells
are capable of proliferation in the absence of interleukin-3. With this system, we determined that EAK-induced
cell survival and mitogenesis are dependent upon the Ras/extracellular-signal-regulated protein kinase (ERK)
cascade. Although the phosphatidylinositol-3 kinase pathway is activated upon EAK signaling, it appears to be
dispensable for the biological actions of the Axl kinase. Furthermore, we demonstrated that different threshold
levels of Ras/ERK activation are needed to induce a block to apoptosis or proliferation in 32D cells. Recently,
we have identified an Axl ligand, GAS6. Surprisingly, GAS6-stimulated 32D-Axl cells exhibited no blockage to
apoptosis or mitogenic response which is correlated with the absence of Ras/ERK activation. Taken together,
these data suggest that different extracellular domains dramatically alter the intracellular response of the Axl
kinase. Furthermore, our data suggest that the GAS6-Axl interaction does not induce mitogenesis and that its
exact role remains to be determined.
The transforming gene axl encodes a novel receptor possess-
ing tyrosine kinase activity and was first isolated from the DNA
of patients with chronic myelogenous leukemia (18, 33). The
transforming activity of axl was first identified by a sensitive
nude mouse tumorigenicity assay. The axl gene product dis-
plays homology to several known tyrosine kinases and yet con-
tains unique sequences in the kinase domain (KWIAIE) (33).
The unique positioning of immunoglobulin-like and fibronec-
tin III repeats in the extracellular region makes Axl a struc-
turally novel RTK (receptor tyrosine kinase) with features
resembling those of cellular adhesion molecules such as the
neuronal cell adhesion molecule, fasciculin, and receptor ty-
rosine phosphatases (33). Recently, a growing number of Axl-
related RTKs which are expressed predominantly in the cen-
tral nervous system have been identified (23, 26, 34). Axl,
however, is expressed in developing mesenchymal tissues after
day 7 of murine development. In adult mice, the Axl protein is
found in many tissues including the heart, gonads, Purkinje
cells of the cerebellum, and kidneys (13a). Furthermore, our
preliminary data suggest that overexpression of Axl by using a
b-actin promoter in transgenic mice appears to cause prenatal
lethality (8a). Taken together, these results suggest that Axl
plays a role in normal development. It has been recently dem-
onstrated that the mouse homolog of Axl, adhesion-related
kinase ARK, is able to induce cell aggregation via homophilic
association of the extracellular domain of ARK (2). Moreover,
this homophilic binding induces receptor phosphorylation.
Thus, it is possible that this unique mechanism is employed to
activate this group of RTKs.
To understand the mechanism of Axl-mediated signal trans-
duction, much effort has been focused on the identification of
its ligand. Recently, an Axl ligand, GAS6 (encoded by a growth
arrest-specific gene), has been identified (52). GAS6 was pre-
viously identified and cloned by virtue of its up-regulated ex-
pression upon serum starvation in NIH 3T3 cells (25). In ad-
dition, it has been demonstrated that GAS6 is also a ligand for
the Axl-related RTK rse/Tyro3 (12). Sequence analysis re-
vealed that GAS6 has 44% identity with protein S, a natural
anticoagulation factor. The function of GAS6 activation of
Axl/Tyro3 remains unclear. The mitogenic action of GAS6 in
Axl-expressing cells is, at best, weak (52). It has recently been
proposed that one biological function of GAS6 may be to
potentiate cell proliferation in vascular smooth muscle cells
mediated by Ca21-mobilizing receptors (31). These findings
suggest that unlike ‘‘classical’’ growth factor receptors, Axl and
Axl-related receptors may signal through mechanisms that re-
sult in distinct cellular consequences.
Prior to identification of the Axl ligand GAS6, we initiated
studies of Axl signaling in interleukin-3 (IL-3)-dependent cell
line 32D by using a chimeric receptor containing the epidermal
growth factor (EGF) receptor (EGFR) extracellular and trans-
membrane domains and the Axl kinase domain (EAK [for
EGFR-Axl kinase]). We have previously shown that upon ex-
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ogenous EGF stimulation, 32D-EAK cells are capable of pro-
liferation in the absence of IL-3 (29). While normal growth of
32D cells is absolutely dependent upon IL-3, prolonged acti-
vation of EAK renders these cells permanently independent of
IL-3 or EGF for growth. This factor independence correlates
with overexpression of the Axl receptor. These biological re-
sponses are associated with phosphorylation of EAK on ty-
rosine residues, indicating that activation of the Axl kinase can
induce growth signals in a myeloid cell context.
Herein, we present results demonstrating that EAK signals
through the Ras/extracellular-signal-regulated protein kinase
(ERK) pathway. A panel of EAK mutants and inhibitors of
signaling molecules have enabled us to dissect distinct EAK-
mediated biological outcomes as a result of differential activa-
tion of the Ras/ERK pathway. Intriguingly, although we have
demonstrated that the p85 subunit of the phosphatidylinosi-
tol-3 (PI-3) kinase is associated with the activated Axl kinase
and that the PI-3 kinase activity associated with the receptor
increased moderately upon receptor activation, no measurable
biological consequence of this association was detected. There-
fore, the role of the PI-3 kinase pathway in Axl signaling
appears to be dispensable. Furthermore, the biochemical char-
acterization of GAS6-Axl interactions has revealed that unlike
the EGFR-Axl chimeric receptor, the Ras/ERK pathway is not
involved in GAS6-induced Axl signaling. The biologically dif-
ferent outcomes resulting from EAK signaling compared with
GAS6-Axl interactions suggest that the configuration of the
extracellular domain has a dramatic impact on the downstream
signaling events induced by the intracellular kinase of Axl.
MATERIALS AND METHODS
Generation of mutant EAK constructions. The wild-type EAK construction
was made as described previously (29). Specific mutations in the Axl kinase
domain of EAK were generated with the Altered Sites in vitro mutagenesis
system (Promega). For mutagenesis, the wild-type Axl intracellular domain was
subcloned into the SalI and BamHI sites of the pALTER-1 vector. The primers
for the mutant constructions are as follows (mutated sequences are underlined;




GAGGATTTCGTC-39. Amino acids 779 to 782 were deleted in the EAKDPI-1
mutant, whereas amino acids 821 to 824 were deleted in the EAKDPI-2 mutant.
The double mutant construction EAKDPI was made by using the primers for
both EAKDPI-1 and EAKDPI-2. Following in vitro mutagenesis and sequencing,
the Axl intracellular domain was subcloned into the SalI and SmaI sites of the
pBluescript vector containing the recombinant EGFR (rEGFR) extracellular
and transmembrane domains (29). The entire mutant EAK construction was
then subcloned into the HpaI and XhoI sites of mammalian expression vector
pLXSN (29).
To generate dominant negative ERK mutants under the control of the dexa-
methasone-inducible mouse mammary tumor virus promoter, the coding region
of the hemagglutinin (HA)-tagged ERK52R and ERK71R constructions was
subcloned into the NotI and EcoRI sites of the pMAM expression vector (Clon-
tech). The HA-tagged ERK mutants were kindly provided by M. Cobb. (Uni-
versity of Texas Southwestern Medical Center) (41).
Cell lines, ligand stimulation, and retroviral infections. Murine IL-3-depen-
dent 32D C13 (32D) cells and the murine retrovirus packaging cell line GP1E86
were maintained as previously described (27, 29). The EAK receptor was acti-
vated with human rEGF (100 ng/ml) (GIBCO-BRL). The full-length Axl recep-
tor was activated with human recombinant GAS6 (100 ng/ml) (provided by B.
Varnum, Amgen). Platelet-derived growth factor B chain (PDGF-BB), at a
concentration of 2 ng/ml (Genzyme), was added to activate the human PDGF
receptor (PDGFR) in 32D cells (gift of J. Pierce, National Institutes of Health).
For ligand treatment, 107 cells were serum starved for 4 h in RPMI 1640 at 378C.
Cell were then treated with the appropriate ligand for 10 min at 378C.
The GP1E86 cell line was used to generate recombinant retroviruses contain-
ing various EAK mutant constructs as previously described (29). In brief, the
EAK mutant constructions were transfected with lipofectin (GIBCO-BRL) into
GP1E86 cells. G418-resistant colonies were selected and used to prepare virus
stocks (27). For infection, 106 32D cells were incubated with recombinant ret-
rovirus (105 CFU/ml) for 24 h in medium containing IL-3. Infected 32D cells
were then selected in medium containing IL-3 and G418 (800 mg/ml). Polyclonal
populations were expanded and maintained in the presence of G418.
Transfection of dominant negative ERK mutants. The pMAM, ERK52R/
pMAM, and ERK71R/pMAM plasmids (10 mg of DNA per electroporation)
were introduced into 32D-EAK cells via electroporation by using a Gene Pulser
(Bio-Rad). Population clones were selected in the presence of G418 and myco-
phenolic acid (25 mg/ml) for 10 to 14 days as described previously (35).
Proliferation and survivability assays. To assay the ability of EAK and EAK
mutant derivatives to abrogate IL-3 dependence for proliferation in the presence
of EGF, 4 3 105 log-phase wild-type and mutant EAK-expressing cells were
washed in phosphate-buffered saline and seeded in 32D medium containing EGF
(100 ng/ml) but lacking WEHI-3B cell-conditioned medium (source of IL-3)
(29). Every 3 days, fresh medium was added to the cells. Live, trypan blue-
excluding cells were counted every day to determine the number of viable cells.
The same procedure was used to determine the GAS6-induced IL-3 abrogation
for 32D-Axl cell proliferation. GAS6 was added to cells at 100 ng/ml. The
survivability assays were carried out as described above, except that on day 9 cells
were spun down and reseeded in complete 32D medium containing IL-3. Live,
trypan blue-excluding cells were counted every day to determine the number of
rescued, viable cells.
To assay the effects of dominant negative ERK mutants on EAK-induced
IL-3-independent proliferation, EAK cells harboring pMAM, ERK52R/pMAM,
and ERK71R/pMAM were seeded in IL-3-deficient 32D medium containing
either 1 mM dexamethasone or dimethyl sulfoxide (dissolving agent; Sigma).
Cells were then allowed to proliferate in the presence or absence of EGF and
counted as described above.
Immunoprecipitation, in vitro binding assays, and Western blotting (immu-
noblotting). Cells were lysed on ice in lysis buffer containing 1% Triton X-100 as
previously described (29). For immunoprecipitation, cell lysates were precleared
with 5 mg of normal rabbit immunoglobulin G per ml and then protein A-G–
agarose beads (Santa Cruz) for 1 h at 48C. Precleared lysates were then incu-
bated with anti-rEGFR extracellular domain antiserum (antibody 1382; 1:500;
gift of H. Earp), anti-Axl immunoglobulin-like antibody (1:1,000) (32), or a
monoclonal anti-Shc antibody (2 mg/ml; Transduction Laboratories) from 1 to 2
h to overnight at 48C. Immune complexes were collected with the addition of
protein A-G–agarose. Immunoprecipitates were washed three times with lysis
buffer. For in vitro binding assays, 1 mg of total lysates was mixed with 10 mg of
purified glutathione S-transferase (GST)-Grb2 SH2 fusion protein conjugated to
agarose beads and incubated at 48C for 4 h. Protein complexes were collected by
centrifugation and washed three times with lysis buffer. After heat denaturation
and centrifugation, eluted proteins were separated on sodium dodecyl sulfate
(SDS)-polyacrylamide gels and transferred onto Immobilon membranes (Milli-
pore). Western blotting with the primary antibodies indicated in Results was
performed (29). Detection of immunoreactivity was accomplished with the ECL
system (Amersham). For ERK mobility shift assays, 50 mg of total protein was
loaded onto a 15% low-cross-linking SDS-polyacrylamide gel as described pre-
viously (6).
PI-3 kinase activity assays. For measurement of receptor-associated PI-3
kinase activity, cells were serum starved and treated with ligand as described
above. Assays were performed essentially as described by Whitman et al. (54).
For 32D and 32D-EAK cells, precleared lysates from 2 3 107 cells were incu-
bated for 1 to 2 h with antiserum 1382 at 48C. As a positive control, 32D-
aPDGFR cell lysates were incubated with the anti-PDGFR a subunit antibody
(Genzyme) for 1 to 2 h at 48C (14). Protein A-G–agarose beads were then added
to immune complexes for 1 h. Following three washes in ice-cold phosphate-
buffered saline–1% Nonidet P-40–100 mM Na3VO4, three washes in 10 mM
HEPES (N-2-hydroxyethylpiperazine-N-9-2-ethanesulfonic acid; pH 7.4)–0.5 M
LiCl–100 mM Na3VO4, and three washes in 10 mM HEPES (pH 7.4)–100 mM
NaCl–1 mM EDTA–100 mM Na3VO4, immunoprecipitates were resuspended in
80 ml of reaction buffer (10 mM HEPES [pH 7.4], 20 mMMgCl2, 100 mM NaCl,
1 mM EDTA, 40 mM ATP) containing 0.25 mg of phosphatidylinositol (Avanti)
per ml and [g-32P]ATP (30 mCi). The kinase reaction mixture was incubated for
20 min at 308C with occasional agitation, and then the reaction was stopped by
addition of 20 ml of 8 N HCl. Following chloroform-methanol (1:1) extractions,
the chloroform phase was subjected to thin-layer chromatography analysis.
Raf-1, MEK-1, and ERK kinase assays. In vitro Raf-1, MEK-1, and ERK
kinase activities were determined largely by the method described by Samuels et
al. (44). In brief, immune complexes were prepared by incubating 200 to 300 mg
of cell lysates with anti-Raf-1 antibody (1.5 mg; Santa Cruz), anti-MEK-1 anti-
body (MEK1-NT; 1:1,000 dilution; UBI), and anti-ERK1 antibody (ERK1-CT; 8
mg; UBI). Immune complexes were collected and washed in lysis buffer and then
reaction buffer as previously described (41). All reaction buffers were prepared
and assays were carried out as described by Samuels et al. To assay Raf-1 kinase
activity, immune complexes were incubated in reaction buffer with 50 ng of the
kinase-deficient MEK-1 used as a substrate. A bacterial strain expressing the
kinase-deficient MEK-1 was kindly provided by J. Westwick. This protein was
then purified through an Ni21 column as previously described (9, 53). The in
vitro kinase activity of MEK-1 was determined by carrying out a kinase reaction
containing MEK-1 immune complexes in the presence of 2.5 mg of a GST-
[K71R]erk1 agarose conjugate (UBI). In vitro ERK kinase activity was assessed
by incubating immune complexes in reaction buffer containing 20 mg of myelin
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basic protein (UBI) as the substrate. All reactions were analyzed on SDS-
polyacrylamide gels as previously described (44).
Ras-GTP–Ras-GDP assays. Ras-GTP–Ras-GTP assays were carried out
largely as previously described (17). Briefly, 32D-EAK cells were serum starved
and labeled in phosphate-free RPMI 1640 supplemented with 32P, at 1 mCi/2 3
107 cells for 4 h at 378C. Following labeling, cells were treated with EGF at 100
ng/ml and 378C for 10 min. Cells were lysed and p21ras immunoprecipitations
were carried out as previously described (17). GTP and GDP were separated by
thin-layer chromatography and quantitated in a PhosphorImager.
RESULTS
To elucidate the downstream components involved in Axl
signaling, we used coimmunoprecipitation assays to examine
potential interactions between EAK and a number of known
signaling molecules in vivo, including p21ras-GAP, Raf-1, Shc,
Grb2, phospholipase C-g, and PI-3 kinase. Of these, only the
p85 subunit of the PI-3 kinase was observed to be physically
associated with EAK upon ligand stimulation (see below). In
addition, we examined whether EAK activation would bio-
chemically activate transcription factor NF-kB or mitogen-
activated protein kinases, including ERKs (9, 51). To assess
whether NF-kB is translocated into the nucleus upon EAK
activation, cell lysates were fractionated following EGF stim-
ulation and anti-NF-kB antibody was used to localize NF-kB
(1). Western blot analysis revealed that following EGF stimu-
lation, NF-kB remained in the cytoplasm, indicating the inac-
tive state of this protein (data not shown). Thus, the NF-kB
pathway is not induced by activation of the Axl kinase. Ligand-
induced EAK activation, however, was found to activate the
Ras/ERK pathway. In addition, in vitro binding assays were
used to further examine potential receptor-substrate interac-
tions as presented below in detail.
Grb2 and Shc are adaptor molecules involved in EAK sig-
naling. While EAK was not observed to coimmunoprecipitate
with any of the known SH2-containing linker molecules in vivo
(data not shown), a potential Grb2 binding site, YVNM (also
known as PI-2; see below; 49), was located in the Axl intracel-
lular domain. To determine whether this motif plays a role in
recruiting Grb2 in EAK signaling, in vitro binding assays were
performed to examine potential interactions between EAK
and the SH2 domain of Grb2 fused to the GST protein (GST-
Grb2 SH2). As shown in Fig. 1A, EAK associated with the SH2
domain of Grb2 in a ligand-dependent manner, indicating the
potential involvement of this protein in the activation of p21ras
in EAK signaling (20; see below). To confirm the specificity of
these potential receptor-substrate interactions, we sought to
determine the sequence motif of Axl required for Grb2 asso-
ciation and whether this association requires a functional Axl
kinase domain. Two EAK derivatives containing mutations in
the intracellular domain were therefore constructed. Kinase-
dead mutant protein EAK567R contains a Lys3Arg substitu-
tion in the ATP binding domain, while the EAKDPI-2 mutant
protein has the putative Grb2 and PI-3 kinase binding site
deleted (amino acids 821 to 824) (18, 33). Both mutant pro-
teins were shown to be expressed on the cell surface by fluo-
rescence-activated cell sorter (FACS) analysis at levels similar
to that of wild-type EAK (data not shown) (29). As demon-
strated in Fig. 1A, neither mutant bound to the SH2 domain of
Grb2 molecules in vitro. Thus, the YVNM motif located in the
Axl intracellular domain appears to be important for binding
of both Grb2 and PI-3 kinase (see below). Both mutant pro-
teins were also tested for the ability to be autophosphorylated
in response to ligand stimulation. As expected, no autophos-
phorylation was detected in the kinase-dead mutant protein
whereas the EAKDPI-2 mutant protein underwent ligand-de-
pendent autophosphorylation (see Fig. 4A).
The adaptor protein Shc has been implicated in mediation of
Ras activation downstream of several RTKs (37). As shown in
Fig. 1B, p52 Shc was found to be significantly tyrosine phos-
phorylated in EAK-expressing cells only upon ligand stimula-
tion. Tyrosine phosphorylation of p52 Shc is dependent upon
intact EAK kinase activity, as no Shc phosphorylation was
detected in the kinase-dead mutant protein-expressing cells
following ligand stimulation. It has been documented that Shc
proteins are tyrosine phosphorylated and associate with Grb2
upon treatment with EGF or insulin (36, 37). Since Shc does
not appear to associate with EAK in a ligand-dependent man-
ner (data not shown), we sought to determine if Shc-Grb2
association could be induced upon EAK activation and serve
to recruit guanine nucleotide exchange factor mSOS for acti-
FIG. 1. Characterization of Grb2 binding and Shc-mediated signaling
events following EGF stimulation in quiescent wild-type and mutant EAK-
expressing 32D cells. (A) 32D cell lysates were prepared following EGF stimu-
lation (1) or mock treatment (2) for 10 min at 378C as described in Materials
and Methods. Total cellular protein (1 mg) was mixed with purified GST-Grb2
SH2 protein, separated on an SDS–9% polyacrylamide gel, and analyzed by
immunoblotting with anti-Axl antibody 17-4 (1:5,000). The position of p170 EAK
is indicated. (B) Total cellular protein (800 mg) was immunoprecipitated with an
anti-Shc antibody (1:125; Transduction Laboratories), separated on an SDS–
12% polyacrylamide gel, and analyzed by immunoblotting with an anti-pTyr
antibody (1:1,000; UBI). Molecular sizes are indicated on the left. The position
of p52-phosphorylated Shc is indicated on the right. 32D cells were the parental
cells. EAK567R and EAKDPI-2 (EAK) are the kinase-dead and the Grb2 and
PI-3 kinase binding site EAK mutant proteins, respectively. (C) Total cell lysates
were immunoprecipitated with a monoclonal anti-Shc antibody as for panel B.
Immune complexes were separated on an SDS–15% polyacrylamide gel and
blotted with a monoclonal anti-Grb2 antibody at a 1:5,000 dilution (Transduction
Laboratories). NC, vector-harboring 32D cells.
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vation of p21ras (11, 37, 40, 48). As shown in Fig. 1C, Grb2
coimmunoprecipitated with Shc in EAK-expressing cells but
not in vector-harboring cells in response to foster ligand stim-
ulation (also see Fig. 9C). Taken together, these results suggest
that Grb2 can be recruited to the plasma membrane for acti-
vation of p21ras as an early event in EAK signaling either by
direct binding to the receptor or by Shc-Grb2 complex forma-
tion triggered by Shc phosphorylation. The latter mechanism
for Grb2 recruitment and Ras/ERK activation may account for
the fact that lower levels of ERK activation were seen in cells
expressing EAKDPI-2, which lacks the putative Grb2 binding
site (see below).
To further pursue the possibility that the recruitment of the
Grb2 molecule to Shc in response to Axl kinase activation may
induce p21ras activation, we measured in vivo Ras-GTP/Ras-
GDP ratios (17). An increase in the Ras-GTP/Ras-GDP ratio
of at least twofold was consistently observed in 32D-EAK cells
upon foster ligand stimulation (Fig. 2). We then further char-
acterized the response of downstream signaling molecules
involved in the Ras/ERK pathway to EAK activation. To
determine the activity of known serine/threonine and dual-
specificity kinases downstream of p21ras, namely, Raf-1 and
MEK-1, in vitro kinase assays on enzyme-specific immune
complexes were performed (44). By using kinase-deficient
MEK as a substrate for Raf-1 and the GST-ERK71R fusion
protein, which contains a loss-of-function mutation in the
ERK1 domain, as a substrate for MEK-1, we confirmed the
involvement and ligand-dependent activation of Raf-1 and
MEK-1 in EAK signaling (data not shown). We then investi-
gated whether the ERKs, downstream of MEK (24), are acti-
vated upon EAK activation. p44 and p42 ERK mobility shift
assays were performed. As shown in Fig. 3, both p44 and p42
ERK bands were shifted, indicating phosphorylation and acti-
vation of these two proteins by MEK upon EAK activation. In
contrast, the kinase-dead EAK mutant protein failed to acti-
vate the ERKs. As expected, lower levels of ERK activation
were observed in cells expressing EAKDPI-2. Since the puta-
tive Grb2 docking site is absent in the EAKDPI-2 mutant
protein, these results further confirmed that Shc is partially
responsible for recruiting Grb2 in vivo and activating the Ras/
ERK pathway following EAK activation.
Increased PI-3 kinase activity and its p85 regulatory sub-
unit are associated with activated Axl kinase. Two putative
PI-3 kinase binding sites (YALM [PI-1] and YVNM [PI-2])
have been identified in the Axl intracellular domain (18, 33,
49). To determine whether these are indeed binding sites for
the p85 regulatory subunit and whether this association is im-
portant for Axl biology, potential physical interactions between
EAK and p85 were examined by coimmunoprecipitation as-
says. As shown in Fig. 4B, p85 is associated with EAK in a
ligand-dependent manner. This association is dependent upon
Axl kinase activity, as no binding was detected with kinase-
dead mutant protein EAK567R. Despite the physical interac-
tion between EAK and p85, Western analysis using a phospho-
tyrosine antibody showed that the p85 subunit associated with
the Axl kinase is not phosphorylated (data not shown). To
further define the functional importance of the two putative
PI-3 kinase binding sites, three deletion mutant proteins lack-
ing either one or both binding sites, namely, EAKDPI-1
(YALM), EAKDPI-2 (YVNM), and EAKDPI (YALM and
YVNM), were generated. While cells harboring EAKDPI-2
were successfully generated with comparable levels of EAK
expression (Fig. 4C), we were unable to generate clones with
FIG. 2. Effects of EAK activation on the Ras-GTP/Ras-GDP ratio. Quies-
cent 32D-EAK cells were mock treated (2) or treated with EGF (1) for 10 min
at 378C. Cell lysates were prepared and incubated in the presence (1) or absence
(2) of anti-Ras antibody Y13-259 (3 mg), and bound nucleotides were analyzed
by thin-layer chromatography (see Materials and Methods). A representative
assay is shown, and the positions of ras-bound GTP and ras-bound GDP are
indicated.
FIG. 3. Mobility shift assay of p42 and p44 ERKs in wild-type and mutant
EAK-expressing 32D cells. Quiescent 32D transfectants were either mock
treated (2) or treated with EGF (1) and lysed. A 50-mg sample of total protein
was separated on a low-cross-linking SDS–15% polyacrylamide gel. Western blot
analysis was performed with an anti-ERK1 antibody at a concentration of 0.25
mg/ml (K-23; Santa Cruz). 32D cells was the parental cells. EAK567R is the
kinase-deficient EAKmutant protein. EAKM824A is the PI-3 kinase binding site
mutant protein, whereas EAKDPI-2 is deficient in both Grb2 and PI-3 kinase
binding. The positions of the phosphorylated forms of ERKs p44 and p42 are
indicated on the right.
FIG. 4. Receptor autophosphorylation and p85 association of wild-type and
mutant EAKs. Quiescent wild-type and mutant EAK-expressing 32D cells were
either mock treated (2) or treated with EGF (1) for 10 min at 378C. Cells were
lysed, and EAK complexes were immunoprecipitated with the anti-rEGFR an-
tibody 1382 (1:500). Western analysis was performed as described in Materials
and Methods. The mutant EAK-expressing 32D cells used are described in the
legend to Fig. 3. (A) The upper half of the immunoblot (cut at the 110-kDa
mark) was incubated with an anti-pTyr antibody (1:1,000; UBI). The 170-kDa
EAK chimeric receptor is indicated. (B) The lower half of the immunoblot was
incubated with a monoclonal anti-p85 antibody (1:1,000; UBI), showing that p85
binding is dependent upon an active EAK. The position of the p85 subunit of the
PI-3 kinase is indicated. (C) To quantitate the amount of total protein loaded in
each lane, the pTyr immunoblot was stripped and reprobed with anti-Axl C-
terminal antibody 17-4 (1:5,000).
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sufficiently high levels of expression of the EAKDPI-1 and
EAKDPI proteins for direct comparison with wild-type EAK in
binding assays. Since the PI-2 site represents a better consen-
sus for PI-3 kinase binding (49), we focused only on EAKDPI-
2-expressing cells for the subsequent biochemical and biolog-
ical studies. As shown in Fig. 4A and B, the EAKDPI-2 mutant
protein failed to bind to p85, although it still undergoes ligand-
dependent autophosphorylation. To determine the functional
consequences of p85 binding to EAK, we measured the PI-3
kinase activity associated with the Axl kinase in response to
foster ligand stimulation (54). As shown in Fig. 5, an average of
a two- to threefold increase in PI-3 kinase activity associated
with EAK was observed after ligand stimulation, indicating
that the recruitment of PI-3 kinase by the Axl kinase activates
this lipid kinase.
As mentioned above, the putative PI-2 site, YVNM, may
also be a binding site for Grb2 molecules (49). Thus, biochem-
ical and biological consequences observed as a result of
EAKDPI-2 mutant signaling may be influenced by both the
Ras/ERK and PI-3 kinase pathways. To dissect the involve-
ment of PI-3 kinase in EAK signaling, we constructed EAK
mutant protein EAKM824A, which contains a Met3Ala sub-
stitution at the 13 position in the YVNM motif (YVNA).
Since the methionine residue at the13 position is known to be
critical for PI-3 kinase binding, this mutant protein should
affect PI-3 kinase binding but not Grb2 docking (19, 49). By
FACS analysis, we observed the expression of this mutant
protein on the cell surface at about 70% of that of EAK. As
will be discussed below, the reduced level of EAKM824A ex-
pression does not appear to impair the ability of receptor-me-
diated, IL-3-independent proliferation in 32D cells. As shown
in Fig. 6B, mutant protein EAKM824A failed to bind to the
p85 subunit of PI-3 kinase yet underwent ligand-dependent auto-
phosphorylation (Fig. 6A). Consistent with the FACS analysis,
slightly lower levels of EAKM824A than wild-type receptor
expression were observed (Fig. 6C). Because lower levels of
EAKM824A are expressed in these cells, we exposed these gels
for an extended period of time and found no association be-
tween p85 and EAKM824A (data not shown). Furthermore,
the Ras/ERK pathway remains intact in EAKM824A-express-
ing cells, as demonstrated by the ability of the EAKM824A
mutant protein to bind GST-Grb2 SH2 in vitro, to activate p52
Shc, to promote Shc-Grb2 complex formation (data not shown),
and to induce ERK activation Fig. 3).
EAK-induced proliferation is associated with full activation
of the Ras/ERK pathway. We have previously demonstrated
that EAK, when activated by EGF in IL-3-dependent 32D
cells, can abrogate the IL-3 dependence for proliferation (29).
To further characterize the role of individual pathways in Axl
biology, 32D-EAK mutants deficient in either intrinsic kinase
activity or p85 binding were subjected to EGF-dependent
growth assays in the absence of IL-3. These cells were stimu-
lated with EGF to determine whether these mutants would
respond to the foster ligand for proliferation in the absence
of IL-3. As shown in Fig. 7A, 32D cells expressing the
EAKM824A mutant protein lacking the binding site for the
PI-3 kinase p85 subunit were capable of undergoing IL-3-
independent proliferation as efficiently as wild-type EAK-ex-
pressing cells. By contrast, EAK567R- and EAKDPI-2-express-
ing cells failed to respond to EGF stimulation for growth in
the absence of IL-3. Since Ras/ERK activation is partially
impaired in EAKDPI-2-expressing cells, these results fur-
ther demonstrate that both the kinase activity and an intact
Ras/ERK pathway are essential for EAK-induced mitogenesis
in 32D cells. However, the fact that cells expressing the
EAKM824A mutant protein are fully capable of proliferating
in the absence of IL-3 suggests that the PI-3 kinase pathway is
dispensable in EAK-induced mitogenesis.
Although certain oncogenes do not induce proliferation in
32D cells, they exert their action by blocking programmed cell
death that results upon cytokine withdrawal. To determine
whether any of the mutants which failed to elicit IL-3-indepen-
dent proliferation could sustain survival in the absence of IL-3,
cells were rescued by using IL-3 after 9 days of IL-3 starvation.
As shown in Fig. 7B, EAKDPI-2-expressing cells were capable
of survival for 9 days of IL-3 deprivation only when stimulated
with EGF, whereas kinase-dead EAK567R mutant protein-
expressing cells failed to be rescued by IL-3. These results
further indicate that full activation of the Ras/ERK signaling
FIG. 5. Coimmunoprecipitation of PI-3 kinase activity with EAK in 32D
cells. Quiescent 32D, 32D-EAK, and 32D-aPDGFR cells (positive control) were
either mock treated (2) or treated with the indicated growth factor (1) for 10
min at 378C. Cell lysates were prepared, and 1 mg of total cellular protein was
immunoprecipitated with either antibody 1382 (32D and 32D-EAK cells) or the
anti-human aPDGFR antibody (32D-aPDGFR cells) as described in Materials
and Methods. Immune complexes were then subjected to a PI-3 kinase assay (see
Materials and Methods). The position of PI-3 phosphate (PIP) is indicated. A
representative result of three independent experiments is shown.
FIG. 6. Characterization of receptor autophosphorylation and p85 associa-
tion of the EAKM824A mutant protein. Quiescent wild-type and mutant EAK-
expressing 32D cells were either mock treated (2) or treated with EGF (1) for
10 min at 378C. Cells were lysed, and EAK complexes were immunoprecipitated
with anti-rEGFR antibody 1382 (1:500). Western analysis was performed as
described in Materials and Methods. The mutant EAK-expressing 32D cells used
are described in the legend to Fig. 3. (A) The upper half of the immunoblot (cut
at the 110-kDa mark) was incubated with an anti-pTyr antibody (1:1,000; UBI).
The position of the 170-kDa EAK chimeric receptor (p170) is indicated. (B) The
lower half of the immunoblot was incubated with a monoclonal anti-p85 antibody
(1:1,000; UBI), showing that p85 binding is dependent upon an active EAK. The
position of the p85 subunit of the PI-3 kinase is indicated. (C) To quantitate the
amount of total protein loaded in each lane, the pTyr immunoblot was stripped
and reprobed with anti-Axl C-terminal antibody 17-4 (1:5,000).
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pathway is essential for EAK-induced, IL-3-independent pro-
liferation in 32D cells. However, a lower threshold of Ras/ERK
activation is sufficient for the survival of these cells.
To confirm the importance of the Ras/ERK pathway in
EAK-induced proliferation, molecules interfering with the
function of the p21ras/ERK pathway were introduced into 32D-
EAK cells. First, HA-tagged, dominant negative ERK52R
(ERK2) and ERK71R (ERK1) mutant proteins were ex-
pressed under the control of the mouse mammary tumor virus
long terminal repeat-inducible promoter in 32D-EAK cells
(41). As shown in Fig. 8A, dexamethasone-induced ERK52R
and ERK71R expression was observed. Following dexametha-
sone induction, blockage of EGF-induced activation of the
endogenous ERKs in 32D-EAK cells expressing the ERK52R
and ERK71R constructions was observed (data not shown).
Upon dexamethasone induction, EAK cells expressing either
the ERK52R or the ERK71R construction failed to respond
fully to EGF-induced proliferation, whereas EGF-induced
proliferation in control EAK cells was not affected (Fig. 8B).
The functional redundancy of the p44 and p42 ERKs and the
fact that other pathways may be involved in EAK-mediated
growth activities may explain why only 40 to 50% inhibition of
EGF-dependent proliferation was observed in these cells (9).
A farnesyltransferase inhibitor which blocks p21ras-dependent
signal transduction transformation was administered to 32D-
EAK cells to determine whether this inhibitor affects EAK-
induced proliferation (6, 22). Inhibition of EAK-mediated pro-
liferation to the level induced by the dominant negative ERK
mutants was achieved by this Ras inhibitor (data not shown).
These results further demonstrate that the Ras/ERK pathway
is involved in the mitogenic activity of EAK in 32D cells.
GAS6-Axl interactions result in downstream signaling
events distinct from EAK-mediated signal transduction. We
have initiated studies of the chimeric receptor EAK in the
hope of understanding the mechanism whereby the activated
FIG. 7. Proliferation and rescue assays of 32D cells expressing wild-type and
mutant EAKs in response to stimulation with EGF. Cells (4 3 105) were seeded
in RPMI 1640 medium containing 15% fetal bovine serum in the presence or
absence of EGF (100 ng/ml). Fresh medium supplemented with EGF was added
every third day. (A) Proliferation assay. Live, proliferative cells were counted
every day on the basis of the trypan blue exclusion method. These results show
that EAK-induced proliferation is dependent upon EAK kinase activity and full
activation of the Ras/ERK pathway but not PI-3 kinase subunit p85 binding.
Symbols:■, EAK plus EGF;F, EAKM824A plus EGF;å, EAKDPI-2 plus EGF;
ë, EAK567R plus EGF; h, EAK minus EGF; E, EAKM824A minus EGF; Ç,
EAKDPI-2 minus EGF; è, EAK567R minus EGF. (B) Following 9 days of EGF
treatment, wild-type and mutant EAK-expressing cells were spun down and
reseeded in complete 32D medium containing IL-3. Since cells expressing wild-
type EAK and EAKM824A proliferate in IL-3-deficient medium supplemented
with EGF, only results for other EAK mutants are shown. These data demon-
strate that EAKDPI-2 is capable of sustaining 32D cell survival after IL-3 with-
drawal. Results are shown as the means and standard deviations of three repli-
cates per point. The mutant proteins tested were EAKDPI-2 (Grb2 and p85
binding deficient), EAK567R (kinase dead), and EAKM824A (p85 binding de-
ficient). Symbols: F, EAK plus EGF; E, Axl plus GAS6.
FIG. 8. Effects of dominant negative ERK mutants on EAK-induced pro-
liferation of 32D cells in the absence of IL-3. (A) Dexamethasone (Dex)-induced
expression of the ERK71R and ERK52R constructions. 32D-EAK cells express-
ing either the parental pMAM vector or the HA-tagged ERK71R and ERK52R
constructions were treated with dimethyl sulfoxide (2) or 1 mM dexamethasone
(1) for 24 h at 378C. Cells were then lysed and subjected to Western analysis, as
described in Materials and Methods, with an anti-HA antibody (12CA5; Boehr-
inger Mannheim) at a concentration of 2 mg/ml. The positions of the p44 ERK1
and p42 ERK2 mutant proteins are indicated. (B) Assay of proliferation of
32D-EAK cells expressing the dominant negative ERKs. Cells (4 3 105) were
seeded in RPMI 1640 medium containing 15% fetal bovine serum supplemented
with EGF (100 ng/ml) in the presence or absence of dexamethasone (1 mM).
Fresh medium supplemented with EGF and dexamethasone was added every
third day. Live, trypan blue-excluding, proliferative cells were counted every day.
Results are shown as the means and standard deviations of three replicates per
point. ■, dexamethasone; p, EGF; h, dexamethasone plus EGF.
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Axl kinase transduces signals. Concomitant with this work, an
intensive effort has been made to identify the cognate ligand
for Axl. Very recently, we have identified GAS6 as an Axl
ligand (52). GAS6 is homologous to vitamin K-dependent an-
ticoagulation factor protein S, and its expression is dramati-
cally increased in quiescent NIH 3T3 cells (25). The biological
function of GAS6 is unknown, although this ligand is weakly
mitogenic in only a few Axl-expressing cell lines (8a). As pu-
rified GAS6 became available, we initiated biochemical anal-
yses similar to the work presented above for EAK studies to
determine downstream events resulting from GAS6-Axl inter-
actions. Although GAS6 stimulation resulted in Axl autophos-
phorylation in 32D cells (Fig. 9A) with an intensity comparable
to that caused by EGF stimulation in EAK-expressing cells,
this Axl activation did not result in activation of the Ras/ERK
pathway, as was seen in EAK-expressing cells after EGF stim-
ulation (Fig. 9B and C). This conclusion is based on two find-
ings: the absence of Shc phosphorylation and Shc-Grb2 com-
plex formation and the lack of ERK mobility shift after GAS6
administration. On the other hand, the p85 subunit of the PI-3
kinase is associated with the autophosphorylated Axl kinase in
a GAS6-dependent fashion, similar to the findings in the EAK
system (Fig. 9D). To rule out the trivial possibility that the
differences in downstream signaling observed between EAK
and Axl were due to lower levels of Axl expression, levels of
receptor expression were determined and found to be compa-
rable (Fig. 9E).
Given the differences in activation of the biochemical path-
ways, we examined the ability of the GAS6-Axl interaction to
induce a mitogenic response. To this end, we assessed the
ability of Axl-transfected 32D cells to abrogate dependence on
IL-3 for proliferation in response to GAS6. 32D-Axl cells were
seeded in medium containing GAS6 but not IL-3. In contrast
to the effect of EGF on 32D-EAK cells, no proliferation was
observed in 32D-Axl cells treated with GAS6 (Fig. 10). In
dose-response experiments, no proliferation of Axl-32D cells
was observed, even in the presence of 500 ng of GAS6 per ml
(data not shown). Despite the absence of a mitogenic response,
it was possible that GAS6 activation of Axl would sustain
survival of 32D-Axl cells upon IL-3 withdrawal. When this was
tested in a stringent 9-day IL-3 withdrawal assay, no 32D-Axl
cells survived (data not shown). Taken together, these results
suggest that GAS6 stimulation of the full-length Axl receptor
kinase results in cellular responses distinct from those of the
chimeric EGFR-Axl receptor kinase.
DISCUSSION
Biological and biochemical characterization of chimeric re-
ceptors consisting of a known extracellular ligand binding do-
main and a kinase domain from an orphan receptor has been
proven to be a fruitful approach for studying the function of
tyrosine kinases (45, 55). The assumption that chimeric recep-
tors possess the same biochemical and biological properties as
the wild-type counterparts from which the intracellular domain
was derived has been validated in a number of studies (45, 55).
For example, an EGFR-nerve growth factor receptor chimera
was able to induce neurite outgrowth in response to EGF in rat
pheochromocytoma PC12 cells. Bioassays have demonstrated
a good concordance between the behavior of the EGFR-ret
chimera and that of the RET/PTC oncogene, an activated ver-
sion of ret. In addition, similar patterns of substrate tyrosine
phosphorylation by EGFR/erbB-2 and by constitutively active
gp185erbB-2 have been reported. To initially dissect the func-
tional requirements responsible for Axl-induced proliferation
of the IL-3-dependent myeloid cell line 32D, we have used an
EGFR-Axl chimera (EAK) to identify downstream signaling
components resulting from the foster ligand-receptor interac-
tion (29). Our results demonstrated that differential activation
of the Ras/ERK pathway results in distinct biological conse-
quences. As shown by growth and survivability assays of a
panel of EAK derivatives, EAK-induced mitogenesis requires
full activation of the Ras/ERK pathway whereas partial acti-
vation of this pathway is sufficient for cell survival. Although
EAK-associated PI-3 kinase activity appeared to increase mod-
erately upon EGF stimulation, the biological function of this
lipid kinase in EAK-induced signaling remains unclear.
As an early event in p21ras activation, we have shown that
two functional routes are responsible for recruiting Grb2 adap-
tor molecules for p21ras activation. First, we have shown li-
gand-dependent EAK-Grb2 association by in vitro binding as-
says. Secondly, although EAK does not appear to directly
associate with p52 Shc molecules, EAK activation nevertheless
stimulates tyrosine phosphorylation of p52 Shc and complex
formation between Shc and Grb2, a hallmark for recruitment
of mSOS for p21ras activation on the plasma membrane (20,
37). Since no ligand-dependent physical interaction between
EAK and p52 Shc was observed by coimmunoprecipitation and
in vitro binding assays, an intriguing possibility is that p52 Shc
is phosphorylated by an unidentified substrate of EAK. Con-
sistent with our observation that Shc phosphorylation and Shc-
Grb2 complex formation are early events in the activation of
the Ras/ERK pathway is the recent report that the phosphor-
ylation of Shc and the binding of Grb2 to Shc are the prereq-
uisites for IL-4-induced p21ras activation (38). In addition, as
seen in other cases of receptor-mediated Ras/ERK activation,
EAK activation induces p21ras-dependent events, including ac-
tivation of Raf-1, MEK-1, and ERKs (Fig. 3) (28, 30).
Two potential p85 binding sites identified in the Axl intra-
cellular domain prompted us to investigate the involvement of
PI-3 kinase in Axl biology. We have shown that the p85 subunit
is recruited to the Axl kinase domain in a ligand-dependent
fashion (Fig. 4). By deletion mutagenesis, we identified one
binding site as YVNM (PI-2; amino acids 821 to 824), located
near the C terminus of the Axl protein. Another potential p85
binding site, YALM (PI-1), is located N terminal of the PI-2
binding site in the Axl intracellular domain. Although several
attempts were made to determine whether this site is also
important for p85 binding, transfectants bearing either
EAKDPI-1 alone or EAKDPI (both sites deleted) expressed
the mutant proteins at very low levels, perhaps because of
decreased stability of the recombinant proteins. Since this poor
expression essentially rendered subsequent biochemical anal-
yses impossible, the importance of the potential N-terminal
p85 binding site is unknown.
As is the case for several other RTKs, the PI-3 kinase asso-
ciated with the Axl kinase appears not to be tyrosine phos-
phorylated (4, 51). While it has been documented that tyrosine
phosphorylation of p85 may not change its catalytic activity,
binding of p85 to the tyrosine-phosphorylated peptides present
in the PDGFR and insulin receptor substrate 1 (IRS-1) leads
to a small increase in PI-3 kinase activity (42). Consistent with
these findings, we observed a two- to threefold increase in PI-3
kinase activity following foster ligand activation of EAK (Fig.
5).
The PI-3 kinase pathway has been implicated in growth
factor-induced proliferation, membrane ruffling, and differen-
tiation (reference 19 and references therein). At least two
downstream targets of the PI-3 kinase have been identified (3,
8). Association of PI-3 kinase activity with the activated
PDGFR and the activated colony-stimulating factor 1 receptor
is correlated with their mitogenic potential (46, 47). The p110
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catalytic subunit of this lipid kinase is homologous to the yeast
Vps34 protein and has been suggested to play a role in vesic-
ular trafficking (16, 19). Furthermore, this p110 subunit has
recently been shown to be coupled with the effector binding
domain of the activated form of p21ras (16, 42). The finding
that ras (Asn-17) expression blocked the growth factor-induced
accumulation of 39 phosphorylated phosphoinositides provides
a potential model for regulation of the PI-3 kinase by the Ras
pathway. Our data, however, revealed no measurable mito-
genic potential of the PI-3 kinase associated with the activated
EAK. Cells expressing PI-3 kinase binding site mutant protein
EAKM824A proliferated in response to EGF in a manner
indistinguishable from that of wild-type EAK-expressing cells
(Fig. 7A). Furthermore, PI-3 kinase activity assays revealed
that in EAKM824A-expressing cells the overall activity of the
PI-3 kinase remains unchanged upon stimulation with a foster
ligand (data not shown). These results rule out the possibility
that PI-3 kinase indirectly plays a role downstream of EAK
signaling.
Since EAK can signal through the Ras/ERK pathway in 32D
cells, we assessed the potential role of this pathway for the
biological response in EAK signaling. Previously we have de-
termined that EGF-induced activation of EAK is mitogenic in
32D cells (29). By using a panel of mutant proteins and bio-
chemical inhibitors, we found that full activation of the Ras/
ERK process is necessary for proliferation. As mentioned
above, EAK mutant proteins defective in p85 binding (EAKM
824A) are able to fully activate Ras/ERK and induce prolifer-
ation. That ERK activation is important for EAK-induced mi-
togenesis is seen in the ability of the dominant negative
ERK52R or ERK71R construction to block EAK-mediated
proliferation by 40 to 50%. This notion is further strengthened
by the fact that blockage of Ras function by the farnesyltrans-
ferase inhibitor impairs EAK-induced proliferation (data not
shown).
32D is a myeloid cell line that proliferates in response to
cytokine signaling and undergoes programmed cell death upon
cytokine withdrawal. Because of these characteristics, 32D
cells have been used not only to assess the mitogenic properties
but also to investigate their capacity to block apoptosis. It was
in similar cells that the antiapoptotic action of bcl-2 was un-
covered (21). By using our Axl mutants, we assessed the role of
the Ras/ERK pathway in sustaining cell survival upon IL-3
withdrawal and found that partial activation of this pathway is
sufficient for EAK-induced cell survival. This is evidenced by
the ability of EAKDPI-2, which only partially activates the
Ras/ERK cascade, to sustain 32D cell growth upon IL-3 with-
drawal (Fig. 7B). Therefore, EAK is capable of blocking ap-
optosis via partial activation of the Ras/ERK pathway.
Through these studies, we have determined that two levels of
the Ras/ERK action are operative in EAK signaling. Full Ras/
ERK activation is necessary for EAK-induced proliferation,
whereas a lower threshold of this activation is required to block
apoptosis following EAK activation.
Recently, we and others have identified a ligand for Axl as
GAS6 (12, 50, 52). With the ligand at hand, we were interested
in the biology and the downstream signaling pathways resulting
from the bona fide Axl ligand-receptor interaction. We found
FIG. 9. Biochemical characterization of downstream events following
GAS6-Axl interactions. (A) Quiescent 32D-Axl or vector-harboring 32D cells
(NC) were stimulated with GAS6 (100 ng/ml) for 10 min at 378C. Cells were lysed
and subjected to immunoprecipitation with an anti-pTyr antibody (1:1,000; UBI)
as described in Materials and Methods. Subsequent Western analysis was per-
formed with anti-Axl antibody 17-4 (1:5,000). The position of p140 Axl is indi-
cated. (B) Following either EGF (EAK) or GAS6 (Axl) stimulation, 50 mg of
total cellular protein was subjected to Western analysis with anti-ERK1 antibody
K-23 (Santa Cruz) at a concentration of 0.25 mg/ml. Positions of unshifted and
shifted p44 and p42 ERKs are indicated. (C) Following ligand treatment (either
EGF for 32D-EAK cells or GAS6 for 32D and 32D-Axl cells), cells were lysed
and subjected to immunoprecipitation with an anti-Shc antibody as described in
Materials and Methods. Following immunoblotting and transfer, the blotted
membrane was cut at the 39-kDa mark. The top half of the membrane was
incubated with an anti-pTyr antibody (1:1,000; UBI), and the bottom half of the
membrane was incubated with an anti-Grb2 antibody (1:5,000; Transduction
Laboratories). The positions of phosphorylated p52 Shc and Shc-associated Grb2
are indicated. (D) Following ligand treatment (either EGF for 32D-EAK cells or
GAS6 for 32D and 32D-Axl cells), cells were lysed and subjected to immuno-
precipitation with an anti-p85 antibody (1:1,000; UBI). Following immunoblot-
ting and transfer, the blotted membrane was incubated with anti-Axl antibody
17-4 (1:5,000). This membrane was then stripped and reprobed with an anti-pTyr
antibody (1:1,000; UBI). These data suggest that p85 coimmunoprecipitates
with the activated kinase domain of either Axl or EAK. The positions of p170
EAK and p140 Axl are indicated. (E) Total cellular proteins (50 mg) of parental
and EAK- and Axl-expressing 32D cells were prepared (see Materials and Meth-
ods) and separated on an SDS–9% polyacrylamide gel. After protein transfer,
the membrane was blotted with anti-Axl antibody 17-4 (1:5,000). Comparable
levels of receptor expression were detected.
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that in Axl-transfected 32D cells, GAS6 stimulation induces
ligand-dependent Axl autophosphorylation (Fig. 9A). Previ-
ously, we have shown that GAS6 can bind to the receptor and
induce autophosphorylation and internalization of the Axl re-
ceptor (52). However, ligand application to 32D-Axl cells did
not induce proliferation, even at a high ligand concentration
(Fig. 10; data not shown). This is in accordance with our earlier
finding that GAS6 is a weak mitogen for some cells but has no
growth-promoting effect on others (52). For a biochemical
explanation for this observation, we assessed the Ras/ERK
cascade and PI-3 kinase binding and found that although Axl
kinase bound to p85 upon GAS6 stimulation, the Ras/ERK
process was not activated, as evaluated by both ERK mobility
shift and p52 Shc phosphorylation assays and Shc-Grb2 com-
plex formation (Fig. 9B, C, and D). These results are consistent
with our findings mentioned above that the Ras/ERK cascade
is necessary for ligand-dependent mitogenesis but that the PI-3
kinase pathway is dispensable. Taken together, these data sug-
gest that the GAS6-Axl interaction may not induce prolifera-
tion, and its primary role remains unclear. In addition, the
nature of the extracellular domain can influence the intracel-
lular signaling pathways used by the Axl kinase.
We propose two potential models invoking unconventional
ligand-receptor interactions that may account for the disparate
biological outcomes of signaling between Axl and EAK. The
first model involves receptor heterodimerization upon GAS6
stimulation. Because the extracellular domain of the EGFR is
known to induce homodimerization upon EGF stimulation
when expressed in 32D cells (36a), EAK-EAK homodimers are
the result of foster ligand stimulation. This homodimerization
is also likely to be accomplished by surface coupling when Axl
is dramatically overexpressed, as was demonstrated in our Axl-
transformed 3T3 cells (33). Supporting this possibility is the
finding that very high levels of Axl expression are able to
transform 3T3 cells, an effect which is associated with consti-
tutive activation of ERKs (8a). In either case, the Axl kinase is
thought to support mitogenesis through activation of the Ras/
ERK pathway. In GAS6-Axl interactions, however, GAS6 may
induce heterodimerization of Axl with another receptor that
has yet to be identified. It has been shown that heterodimer-
ization occurs between homologs in the EGFR family (5; ref-
erences therein). For example, upon binding of the ligand
heregulin (or Neu differentiation factor), heterodimers form
between ErbB2 and ErbB3 and between ErbB2 and ErbB4. It
is thought that heterodimerization between homologous re-
ceptors may determine what SH2-containing molecules will be
recruited for downstream signaling (5, 7). In GAS6-Axl signal-
ing, potentially following a heterodimerization event, a differ-
ent subset of phosphorylated tyrosines may be generated; this
differs from the tyrosine phosphorylation induced by EGF-EAK
interactions. In the PDGFR subfamily, PDGFRa/b heterodimer-
ization can be induced by either PDGF-AB or PDGF-BB stim-
ulation (15, 43). The mitogenic signal elicited following activa-
tion of PDGFR heterodimers is stronger than that induced by
PDGFR homodimers (43). The fact that families of structur-
ally related RTKs and ligands exist makes it possible that
homodimerization and heterodimerization may occur depen-
dent upon the level and type of related RTKs on the cell
surface. This heterogeneity would function to widen the spec-
trum of biological responses resulting from a given family of
receptors. As mentioned above, a number of Axl-related RTKs
have been identified (2, 10, 13, 23, 34). Therefore, it is possible
that heterodimerization between Axl homologs serves to mod-
ulate and diversify downstream signals by differentially recruit-
ing SH2-containing molecules.
An alternate mechanism of Axl activation by GAS6 stimu-
lation, however, may involve homophilic binding via the extra-
cellular domain of Axl. Recent studies have demonstrated that
the murine homolog of Axl, ARK, is capable of promoting cell
aggregation through homophilic binding (2). This homophilic
association, which is putatively characterized by head-to-tail
dimerization of the extracellular domains, results in an in-
crease in receptor phosphorylation. The only other RTK that
has been shown to undergo homophilic binding is DTrk, a
Drosophila RTK highly related to the trk family of mammalian
neurotrophin receptors (39). The Ca21-independent, ho-
mophilic association of DTrk induces receptor phosphorylation
and is thought to be the mechanism by which DTrk regulates
neuronal recognition during development. The conformational
change following homophilic interactions may activate a lim-
ited aspect of the kinase and therefore result in activation of
fewer intracellular signaling partners. Our preliminary results
have indicated that the extracellular domain of Axl can serve as
a partner for the adhesion of Axl-expressing fibroblasts and
32D cells (unpublished data). Because homophilic interactions
may not result in dimerization of the kinase domains of RTKs,
the single activated Axl cytoplasmic domain may interact with
a limited number of downstream signaling partners. This may
also explain the differential involvement of the downstream
components in signaling between EAK and Axl.
In conclusion, our studies on Axl signaling have uncovered
potentially intricate ligand-receptor interactions depending
upon the dimeric nature of the extracellular domain following
ligand stimulation. The same activated Axl kinase in EAK
results in signaling events and biological responses dramati-
cally different from those of full-length Axl. While the biolog-
ical role of GAS6-Axl interactions remains to be determined,
our studies underscore the complexity of ligand-receptor in-
teractions.
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FIG. 10. Assay of 32D-EAK and 32D-Axl cell proliferation. Cells (4 3 105)
were seeded in RPMI 1640 medium containing 15% fetal bovine serum in the
presence of EGF (100 ng/ml) or GAS6 (100 ng/ml). Fresh medium supplemented
with the indicated ligand was added every third day. Live, proliferative cells were
counted every day by the trypan blue exclusion method. These data demonstrate
that 32D-Axl cells are not capable of proliferating in response to GAS6 after IL-3
withdrawal. Results are shown as the means and standard deviations of three
replicates per point. Symbols: F, 32D-EAK; E, 32D-Axl.
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